The metabolic syndrome and its components in pediatric survivors of allogeneic hematopoietic stem cell transplantation. Issue 3 (1st February 2017)

• Record Type: Journal Article
• Authors: Bielorai, Bella; Weintraub, Yael; Hutt, Daphna; Hemi, Rina; Kanety, Hannah; Modan‐Moses, Dalit; Goldstein, Gal; Hadar, Dana; Lerner‐Geva, Liat; Toren, Amos; Pinhas‐Hamiel, Orit
• Is Part Of: Clinical transplantation. Volume 31:Issue 3(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-02-01
• Subjects: dyslipidemia -- hematopoietic stem cell transplantation -- metabolic syndrome -- obesity -- overweight -- total body irradiation -- type 2 diabetes mellitus; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12903
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Metabolic syndrome (MetS) is a known complication after hematopoietic stem cell transplantations (HSCT) that contributes to long‐term morbidity. We assessed the prevalence of components of the MetS in pediatric survivors of allogeneic HSCT and identified associated risk factors. Thirty‐eight patients, median age at HSCT, 8.5 years, were evaluated at a median of 3.9 years post‐HSCT. Overweight or obesity was seen in 23.7% of the patients, 15.8% had hypertension, 15.8% had hypertriglyceridemia, and 13% had low high‐density lipoprotein cholesterol levels according to age and gender. Four (10.5%) met the criteria of MetS; all were transplanted for malignant disease. Twelve patients (31.6%) had at least one component of the MetS. The 5‐year probability of developing components of the MetS revealed that patients with BMI‐ Z score ≥0 at HSCT were significantly at higher risk than those with lower BMI‐ Z . Patients who developed components of the MetS had higher levels of insulin, homeostasis model assessment, uric acid, leptin, and lower adiponectin levels. Multivariable regression analysis revealed that BMI‐ Z ‐score >1.036 at time of evaluation was associated with 4.3‐fold increased risk ( P =.050) and adiponectin levels ≤6 μg/mL were associated with 6.7‐fold increased risk of develop components of the MetS ( P =.007). Overweight and obesity and adiponectin levels may be useful as markers in HSCT survivors.